SecBot SecBot
SECBOTREPLAY Home › Report › RDY

RDY · Dr

DR REDDYS LABORATORIES LTD · 6-K filed Jul 15, 2026 at 09:45 ET

At the news

BEARISHIMPACT 6/10

6-K filed Jul 15, 2026 at 09:45 ET

Dr. Reddy's disclosed a manufacturing impurity issue in the scale-up of its semaglutide injection API, causing a halt in commercial supply for approximately three months. The company now expects to supply only 6-7 million pens in FY27 (down from prior guidance of ~12 million), with no patient safety impact or recall. This is a material negative for near-term revenue from its key GLP-1 product.

  • Impurity (degradation) detected in finished drug product from a scale-up validation batch of semaglutide injection API.
  • Commercial supply halted until process is fixed and re-validated; expected resumption late October/early November 2026.
  • FY27 semaglutide pen guidance revised to 6-7 million pens (from prior ~12 million), with supply concentrated in Q3-Q4.
  • No patient safety impact, no recall of previously supplied product, and no impact on oral semaglutide or existing regulatory filings.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access